Botox® (onabotulinumtoxinA)

Covered: Botox is approved for multiple FDA‑labeled indications (e.g., overactive bladder ≥18, neurogenic detrusor overactivity ≥5, chronic migraine prophylaxis ≥18, upper/lower limb spasticity ≥2, cervical dystonia, primary axillary hyperhidrosis, blepharospasm, strabismus) and specified compendial off‑label uses. Key requirements: approval requires indication‑specific documentation (age limits, trials of prior pharmacologic therapy when required, neurologist/headache specialist consultation for migraine), adherence to dosing/maximum dose and re‑treatment interval limits (typically ≥12 weeks), and demonstrated clinical benefit for reauthorization.

"Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency"

Sign up to see full coverage criteria, indications, and limitations.